Impact of Infection Patterns on the Outcomes of Patients with Hematological Malignancies in Southwest China: A 10-Year Retrospective Case-Control Study

References

• Atkins S, He F. Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies. Infect Dis Clin North Am. 2019;33(2):289–309. doi:10.1016/j.idc.2019.01.001
   PubMed Web of Science ®Google Scholar
• Tau N, Shargian-Alon L, Reich S, et al. Reporting infections in clinical trials of patients with haematological malignancies. Clin Microbiol Infect. 2019;25(12):1494–1500. doi:10.1016/j.cmi.2019.04.029
   PubMed Web of Science ®Google Scholar
• Schulz E, Grumaz S, Hatzl S, et al. Pathogen detection by metagenomic next-generation sequencing during neutropenic fever in patients with hematological malignancies. Open Forum Infect Dis. 2022;9(8):ofac393. doi:10.1093/ofid/ofac393
   PubMed Web of Science ®Google Scholar
• Takeshita K, Ishiwada N, Takeuchi N, et al. Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors. Vaccine. 2022;40(9):1238–1245. doi:10.1016/j.vaccine.2022.01.056
   PubMed Web of Science ®Google Scholar
• Kiderlen TR, Trostdorf K, Delmastro N, Salomon A, de Wit M, Reinwald M. Herpes zoster vaccination rates in hematological and oncological patients-stock taking 2 years after market approval. Healthcare. 2022;10(8):1524. doi:10.3390/healthcare10081524
   Web of Science ®Google Scholar
• Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M. Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(2):189–198. doi:10.1016/j.cmi.2019.09.003
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: current concepts and future directions. Clin Infect Dis. 2018;67(10):1621–1630. doi:10.1093/cid/ciy473
   PubMed Web of Science ®Google Scholar
• Christopeit M, Schmidt-Hieber M, Sprute R, et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2021;100(2):321–336. doi:10.1007/s00277-020-04297-8
   PubMed Web of Science ®Google Scholar
• Hardak E, Avivi I, Berkun L, et al. Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. Infection. 2016;44(4):491–497. doi:10.1007/s15010-016-0873-3
   PubMed Web of Science ®Google Scholar
• Danion F, Duval C, Severac F, et al. Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study. Clin Microbiol Infect. 2021;27(11):1644–1651. doi:10.1016/j.cmi.2021.02.021
   PubMed Web of Science ®Google Scholar
• Huang LW, Wong SW, Andreadis C, Olin RL. Updates on hematologic malignancies in the older adult: focus on acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma. Curr Oncol Rep. 2019;21(4):35. doi:10.1007/s11912-019-0778-2
   PubMed Web of Science ®Google Scholar
• Amanati A, Sajedianfard S, Khajeh S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis. 2021;21(1):636. doi:10.1186/s12879-021-06243-z
   PubMed Web of Science ®Google Scholar
• Chen XC, Xu J, Wu DP. Clinical characteristics and implications of mixed candida/bacterial bloodstream infections in patients with hematological diseases. Eur J Clin Microbiol Infect Dis. 2020;39(8):1445–1452. doi:10.1007/s10096-020-03863-2
   PubMed Web of Science ®Google Scholar
• Manjappachar NK, Cuenca JA, Ramirez CM, et al. Outcomes and predictors of 28-day mortality in patients with hematologic malignancies and septic shock defined by sepsis-3 criteria. J Natl Compr Canc Netw. 2022;20(1):45–53. doi:10.6004/jnccn.2021.7046
   PubMed Web of Science ®Google Scholar
• Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110(10):3532–3539. doi:10.1182/blood-2007-05-091942
   PubMed Web of Science ®Google Scholar
• Liu Y, Ling L, Wong SH, et al. Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. EClinicalMedicine. 2021;37:100955. doi:10.1016/j.eclinm.2021.100955
   PubMedGoogle Scholar
• Torres JP, Labrana Y, Ibanez C, et al. Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia. Pediatr Infect Dis J. 2012;31(9):889–893. doi:10.1097/INF.0b013e31825c4b7e
   PubMed Web of Science ®Google Scholar
• Liu YN, Zhang YF, Xu Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. Lancet Microb. 2023;4(5):e330–e339. doi:10.1016/S2666-5247(23)00031-9
   PubMedGoogle Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45. doi:10.1086/599376
   PubMed Web of Science ®Google Scholar
• Hage CA, Carmona EM, Epelbaum O, et al. Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2019;200(5):535–550. doi:10.1164/rccm.201906-1185ST
   PubMed Web of Science ®Google Scholar
• Naranjo RL. A pretest for choosing between logrank and Wilcoxon tests in the two-sample problem. METRON Int J Stat. 2010;68:111–125.
   Google Scholar
• David O, Fruchtman Y, Sergienko R, Kapelushnik J, Leibovitz E. The Infectious and noninfectious etiology, clinical picture and outcome of neutropenia in immunocompetent hospitalized children. Pediatr Infect Dis J. 2018;37(6):570–575. doi:10.1097/INF.0000000000001893
   PubMed Web of Science ®Google Scholar
• Bou Chebl R, Safa R, Sabra M, et al. Sepsis in patients with haematological versus solid cancer: a retrospective cohort study. BMJ Open. 2021;11(2):e038349. doi:10.1136/bmjopen-2020-038349
   PubMed Web of Science ®Google Scholar
• Chen CY, Sheng WH, Tien FM, et al. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008–2013. J Microbiol Immunol Infect. 2020;53(1):106–114. doi:10.1016/j.jmii.2018.01.002
   PubMedGoogle Scholar
• On S, Rath CG, Lan M, et al. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022;197(1):63–70. doi:10.1111/bjh.18051
   PubMed Web of Science ®Google Scholar
• Souza L, Nouer SA, Morales H, et al. Epidemiology of invasive fungal disease in haematologic patients. Mycoses. 2021;64(3):252–256. doi:10.1111/myc.13205
   PubMed Web of Science ®Google Scholar
• Oh SM, Byun JM, Chang E, et al. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis. Sci Rep. 2021;11(1):22160. doi:10.1038/s41598-021-01716-2
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230. doi:10.1093/jac/dky286
   PubMed Web of Science ®Google Scholar
• Xiao M, Sun ZY, Kang M, et al. Five-year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. J Clin Microbiol. 2018;56(7):e00577–00518. doi:10.1128/JCM.00577-18
   PubMed Web of Science ®Google Scholar
• Pu S, Niu S, Zhang C, et al. Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China. J Microbiol Immunol Infect. 2017;50(1):97–103. doi:10.1016/j.jmii.2015.01.005
   PubMedGoogle Scholar
• Puig-Asensio M, Ruiz-Camps I, Fernandez-Ruiz M, et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clin Microbiol Infect. 2015;21(5):491.e1–10. doi:10.1016/j.cmi.2014.12.027
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Hori D, Sano H, Suzuki D, Kishimoto K, Kobayashi K. Risk factors for invasive fungal infection in children and adolescents with hematologic and malignant diseases: a 10-year analysis in a single institute in Japan. Pediatr Infect Dis J. 2018;37(12):1282–1285. doi:10.1097/INF.0000000000002010
   PubMed Web of Science ®Google Scholar
• Badali H, Canete-Gibas C, McCarthy D, et al. Species distribution and antifungal susceptibilities of aspergillus section fumigati isolates in clinical samples from the United States. J Clin Microbiol. 2022;60(5):e0028022. doi:10.1128/jcm.00280-22
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Reddy RK, Tandon P, et al. Prediction of fungal infection development and their impact on survival using the NACSELD Cohort. Am J Gastroenterol. 2018;113(4):556–563. doi:10.1038/ajg.2017.471
   PubMed Web of Science ®Google Scholar
• van der Net JB, Janssens AC, Eijkemans MJ, Kastelein JJ, Sijbrands EJ, Steyerberg EW. Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies. Eur J Hum Genet. 2008;16(9):1111–1116. doi:10.1038/ejhg.2008.59
   PubMed Web of Science ®Google Scholar
• Hauck C, Cober E, Richter SS, et al. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect. 2016;22(6):513–519. doi:10.1016/j.cmi.2016.01.023
   PubMed Web of Science ®Google Scholar
• Di Domenico EG, Marchesi F, Cavallo I, et al. The impact of bacterial biofilms on end-organ disease and mortality in patients with hematologic malignancies developing a bloodstream infection. Microbiol Spectr. 2021;9(1):e0055021. doi:10.1128/Spectrum.00550-21
   PubMed Web of Science ®Google Scholar
• Lu L, Xu C, Tang Y, et al. The threat of carbapenem-resistant gram-negative bacteria in patients with hematological malignancies: unignorable respiratory non-fermentative bacteria-derived bloodstream infections. Infect Drug Resist. 2022;15:2901–2914. doi:10.2147/IDR.S359833
   PubMed Web of Science ®Google Scholar
• McArdle AJ, Turkova A, Cunnington AJ. When do co-infections matter? Curr Opin Infect Dis. 2018;31(3):209–215. doi:10.1097/QCO.0000000000000447
   PubMed Web of Science ®Google Scholar
• Gorsich EE, Etienne RS, Medlock J, et al. Opposite outcomes of coinfection at individual and population scales. Proc Natl Acad Sci USA. 2018;115(29):7545–7550. doi:10.1073/pnas.1801095115
   PubMed Web of Science ®Google Scholar
• Lemiale V, Pons S, Mirouse A, et al. Sepsis and septic shock in patients with malignancies: a groupe de recherche respiratoire en reanimation onco-hematologique study. Crit Care Med. 2020;48(6):822–829. doi:10.1097/CCM.0000000000004322
   PubMed Web of Science ®Google Scholar
• Oeyen SG, Benoit DD, Annemans L, et al. Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study. Intensive Care Med. 2013;39(5):889–898. doi:10.1007/s00134-012-2791-x
   PubMed Web of Science ®Google Scholar
• Xiang MJ, Chen GL. Impact of cancer on mortality rates in patients with sepsis: a meta-analysis and meta-regression of current studies. World J Clin Cases. 2022;10(21):7386–7396. doi:10.12998/wjcc.v10.i21.7386
   PubMed Web of Science ®Google Scholar
• Yadav S, Mathew R, Sahu AK, et al. Prognostic value of serum procalcitonin levels in patients with febrile neutropenia presenting to the emergency department. J Emerg Med. 2021;60(5):641–647. doi:10.1016/j.jemermed.2020.12.010
   PubMed Web of Science ®Google Scholar
• Liang P, Yu F. Value of CRP, PCT, and NLR in prediction of severity and prognosis of patients with bloodstream infections and sepsis. Front Surg. 2022;9:857218. doi:10.3389/fsurg.2022.857218
   PubMed Web of Science ®Google Scholar
• Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the multinational association of supportive care in cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, −6, −8 and −10. Eur J Cancer Care. 2007;16(6):475–483. doi:10.1111/j.1365-2354.2007.00780.x
   PubMed Web of Science ®Google Scholar
• Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8(5):R291–298. doi:10.1186/cc2893
   PubMed Web of Science ®Google Scholar